| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 73.558 | 74.710 | 102.897 | 115.321 | 131.434 | 108.285 | 163.212 | 243.806 | 299.461 | 286.367 |
| Total Income - EUR | 73.726 | 75.823 | 111.923 | 115.486 | 134.271 | 111.440 | 174.443 | 249.664 | 301.507 | 293.562 |
| Total Expenses - EUR | 66.011 | 45.389 | 57.754 | 56.074 | 79.347 | 79.053 | 90.297 | 100.905 | 109.761 | 123.810 |
| Gross Profit/Loss - EUR | 7.715 | 30.435 | 54.169 | 59.412 | 54.924 | 32.387 | 84.146 | 148.759 | 191.746 | 169.752 |
| Net Profit/Loss - EUR | 5.759 | 28.918 | 52.260 | 58.259 | 53.610 | 31.388 | 82.555 | 146.466 | 189.257 | 161.126 |
| Employees | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 |
Check the financial reports for the company - Orl Endoclinic Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 28.004 | 19.327 | 42.376 | 33.942 | 45.947 | 87.323 | 57.949 | 49.474 | 52.057 | 72.623 |
| Current Assets | 25.181 | 25.704 | 43.155 | 52.375 | 60.463 | 57.899 | 74.936 | 137.945 | 159.144 | 119.981 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 30 | 0 | 0 | 0 | 0 |
| Receivables | 14.850 | 2.302 | 2.015 | 13.250 | 3.298 | 2.823 | 10.866 | 106.923 | 153.503 | 92.576 |
| Cash | 10.331 | 23.402 | 41.140 | 39.125 | 57.165 | 55.046 | 64.071 | 31.022 | 5.641 | 17.353 |
| Shareholders Funds | 26.616 | 28.971 | 52.312 | 58.311 | 54.005 | 60.867 | 82.675 | 146.515 | 189.306 | 161.174 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 27.224 | 16.298 | 33.385 | 29.088 | 51.103 | 83.707 | 49.850 | 41.330 | 22.740 | 30.937 |
| Income in Advance | 0 | 0 | 0 | 0 | 1.587 | 1.193 | 811 | 0 | 0 | 1.160 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Orl Endoclinic Srl